Drug Trial Radar · NCT07276789
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Dec 8, 2025
Primary completion
Jun 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Integro TheranosticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) infusion in patients undergoing VATS (Video-Assisted Thoracoscopic Surgery) or RATS (Robotic-Assisted Thoracoscopic Surgery) resection of Stage I-II non-small cell lung cancer (NSCLC).
Conditions
- Non Small Cell Lung Cancer (NSCLC)
Interventions
LS301-IT 0.1 mg/kgDrug
Single dose of LS301-IT administed up to 4 days prior to surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinically Significant EventsTime frame: On the day of surgery
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Iowa
Iowa City, Iowa
University of Pennsylvania
Philadelphia, Pennsylvania
University of Texas Southwestern Medical Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.